JP2022522965A5 - - Google Patents

Info

Publication number
JP2022522965A5
JP2022522965A5 JP2021540811A JP2021540811A JP2022522965A5 JP 2022522965 A5 JP2022522965 A5 JP 2022522965A5 JP 2021540811 A JP2021540811 A JP 2021540811A JP 2021540811 A JP2021540811 A JP 2021540811A JP 2022522965 A5 JP2022522965 A5 JP 2022522965A5
Authority
JP
Japan
Prior art keywords
sequence
labrisin
recombinant
amino acid
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021540811A
Other languages
English (en)
Japanese (ja)
Other versions
JP7667569B2 (ja
JP2022522965A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/013752 external-priority patent/WO2020150396A1/en
Publication of JP2022522965A publication Critical patent/JP2022522965A/ja
Publication of JP2022522965A5 publication Critical patent/JP2022522965A5/ja
Application granted granted Critical
Publication of JP7667569B2 publication Critical patent/JP7667569B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021540811A 2019-01-15 2020-01-15 組換えラブリシン、並びにそれを使用するための組成物及び方法 Active JP7667569B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962792660P 2019-01-15 2019-01-15
US62/792,660 2019-01-15
PCT/US2020/013752 WO2020150396A1 (en) 2019-01-15 2020-01-15 Recombinant lubricins, and compositions and methods for using the same

Publications (3)

Publication Number Publication Date
JP2022522965A JP2022522965A (ja) 2022-04-21
JP2022522965A5 true JP2022522965A5 (cg-RX-API-DMAC7.html) 2023-01-20
JP7667569B2 JP7667569B2 (ja) 2025-04-23

Family

ID=71614494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540811A Active JP7667569B2 (ja) 2019-01-15 2020-01-15 組換えラブリシン、並びにそれを使用するための組成物及び方法

Country Status (5)

Country Link
US (2) US12703727B2 (cg-RX-API-DMAC7.html)
EP (1) EP3911355A4 (cg-RX-API-DMAC7.html)
JP (1) JP7667569B2 (cg-RX-API-DMAC7.html)
CN (2) CN113573724B (cg-RX-API-DMAC7.html)
WO (2) WO2020150396A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6755952B2 (ja) * 2016-09-14 2020-09-16 レボテック カンパニー,リミティド 人工組織前駆体及びそれを調製する方法
JP7667569B2 (ja) * 2019-01-15 2025-04-23 コーネル ユニバーシティー 組換えラブリシン、並びにそれを使用するための組成物及び方法
CN114107437A (zh) * 2021-11-30 2022-03-01 南通大学 一种基于荧光素酶亚基互补的主蛋白酶抑制剂活性检测系统及在药物筛选中的应用
CN115144303B (zh) * 2022-08-01 2025-05-16 中国科学院自动化研究所 基于磁粒子布朗弛豫的细胞质粘度检测方法及应用
CN117106024B (zh) * 2022-10-21 2024-05-24 南京市妇幼保健院 一种人血清多肽agdmp1及其在改善胰岛素抵抗中的应用
WO2025166171A1 (en) * 2024-01-31 2025-08-07 Cornell University Manufacturing and bioprocessing of multispecies biolubricants

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309760B2 (en) * 2001-04-17 2007-12-18 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
WO2005016130A2 (en) * 2003-08-14 2005-02-24 Wyeth Recombinant lubricin molecules and uses thereof
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
US7829679B2 (en) * 2005-08-12 2010-11-09 Riken Mucin-type glycoprotein and use thereof
WO2008133928A2 (en) * 2007-04-27 2008-11-06 The Gi Company, Inc. Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
HRP20150097T1 (hr) 2008-05-07 2015-03-27 The Regents Of The University Of California Terapijska nadopuna i poboljšanje vlaženja površine oka
CA2771110C (en) * 2009-08-13 2019-02-26 Singularis, Inc. Prg4 treatment for interstitial cystitis
US20140187474A1 (en) * 2011-02-16 2014-07-03 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US20150010606A1 (en) * 2013-07-08 2015-01-08 Arthrex, Inc. Intra-articular injection and implant attachment of molecule consisting of lubricin and extracellular superoxide dismutase or hyaluronic acid and extracellular superoxide dismutase
US20180125926A1 (en) * 2013-09-25 2018-05-10 Axcella Health Inc. Compositions and Formulations and Methods of Production and Use Thereof
US9982027B2 (en) 2013-10-22 2018-05-29 Lubris Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
US10500250B2 (en) * 2013-11-26 2019-12-10 Lubris Llc Compositions and methods for inhibiting intercellular interactions
AU2016211694B2 (en) 2015-01-26 2021-11-11 Lubris Llc Use of PRG4 as an anti-inflammatory agent
EP3072957B1 (en) * 2015-03-23 2019-07-10 Lonza Ltd Methods for controlling protein glycosylation
LT3300482T (lt) 2015-05-19 2021-10-25 Lubris Llc Prg4 panaudojimas dinaminio regos aštrumo pagerinimui ir aukštesnės eilės aberacijų sumažinimui
JP6913032B2 (ja) 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
MX381665B (es) 2016-01-13 2025-03-13 Genzyme Corp Star Vectores aav recombinantes que expresan genes osteoprotectores, que incluyen has2 y lubricina, de utilidad en el tratamiento de la osteoartritis y afecciones articulares relacionadas en mamiferos.
WO2017165674A1 (en) 2016-03-23 2017-09-28 International Aids Vaccine Initiative Immunogenic trimers
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
CN109055426B (zh) * 2018-08-06 2021-06-25 智享生物(苏州)有限公司 一种在中华仓鼠卵巢细胞中表达生产类人润滑素的方法
JP7667569B2 (ja) * 2019-01-15 2025-04-23 コーネル ユニバーシティー 組換えラブリシン、並びにそれを使用するための組成物及び方法

Similar Documents

Publication Publication Date Title
JP2022500017A5 (cg-RX-API-DMAC7.html)
JP2021191265A5 (cg-RX-API-DMAC7.html)
WO2025140277A1 (zh) 一种重组人iv型胶原蛋白及其制备方法
IE58317B1 (en) Human insulin-like growth factor (igf) produced from a recombinant host, process, expression vector and recombinant host therefore, and igf-containing pharmaceutical composition
RU2001110120A (ru) Модифицированный сигнальный пептид энтеротоксина-ii e. coli и микроорганизм, экспрессирующий белок слияния упомянутого пептида с гетерологичным белком
CN107698684A (zh) 包含突变的免疫球蛋白Fc部分的GLP‑1融合蛋白
RU2018121480A (ru) СПОСОБ ПОЛУЧЕНИЯ ХИМИЧЕСКИХ ПРОДУКТОВ ТОНКОГО СИНТЕЗА С ПОМОЩЬЮ CORYNEBACTERIUM, СЕКРЕТИРУЮЩЕЙ МОДИФИЦИРОВАННЫЕ a-1,6-ГЛЮКОЗИДАЗЫ
MX2025009545A (es) Metodos y composiciones para la administracion de sistemas de vector dual otoferlin
RU2019104948A (ru) Генетически модифицированные бактерии, стабильно экспрессирующие ил-10 и инсулин
CN116874576B (zh) 一种重组人源化丝聚蛋白及其制备方法和应用
ZA202404727B (en) N-terminal and/or c-terminal cleaved soluble ph20 polypeptide and use thereof
US10294284B2 (en) Method for preparing C1q recombinant protein
ATE253639T1 (de) Verfahren zur herstellung von peptiden
Hiraoka et al. The cDNA and protein sequences of mouse lactate dehydrogenase B: Molecular evolution of vertebrate lactate dehydrogenase genes A (muscle), B (heart) and C (testis)
CN109021071B (zh) 肽及其制备方法和用途
EP4471138A1 (en) Iga protease truncation, fusion protein comprising iga protease truncation, and use thereof
GB2614166A (en) T cell receptors recognizing R273C or Y220C mutations in P53
CN101821286B (zh) 生产成熟的重组螨i类变应原的方法
CN102348800A (zh) 融合蛋白、其制备方法及其在重组蛋白表达系统中的应用
EP4099989A2 (en) T cell receptors targeting defective dna repair proteins
JPWO2024029529A5 (cg-RX-API-DMAC7.html)
CN114651063B (zh) 用于表达重组治疗性肽的n-末端延伸序列
WO2023011486A1 (zh) 高效引入赖氨酸衍生物的氨酰基-tRNA合成酶及其应用
Rykov et al. Designing a cell surface display system of protein domains in lactobacilli based on S-Layer proteins of Lactobacillus brevis ATCC 367
KR20170100367A (ko) 재조합 상피세포성장인자의 제조방법